HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group.

AbstractOBJECTIVE:
To describe the clinical course of patients with angioimmunoblastic lymphadenopathy (AILD)-type lymphoma with a sequential treatment with prednisone and COPBLAM/IMVP-16.
DESIGN:
A multicenter, prospective, nonrandomized trial.
SETTING:
University medical centers and community hospitals.
PATIENTS:
Sixty-seven patients were registered, 28 were excluded, and 39 patients were evaluable for response (median age, 59 years; range, 25 to 82 years) (stages I and II, 10%; stages III and IV, 90%; B symptoms, 74%).
MEASUREMENTS:
Response, survival, and relapse.
INTERVENTION:
Patients initially received prednisone and no further treatment if a complete remission was achieved. Relapsing or refractory patients were treated with COPBLAM/IMVP-16. Patients with life-threatening tumor progression or extension received COPBLAM/IMVP-16 initially. Treatments were chosen in accordance with tumor extension and response to prednisone. Treatment modalities were not compared.
RESULTS:
Twenty-eight patients received primary prednisone, 18 received secondary prednisone, and 11 received primary chemotherapy. The complete response rates (with 95% CIs) were 29% (CI, 12% to 46%), 56% (CI, 33% to 79%), and 64% (CI, 36% to 92%), respectively. The median observation time of surviving patients was 28 months (range, 7 to 53). The median overall survival time was 15 months. The probabilities (with 95% CIs) of overall survival, event-free survival, and relapse at 36 months were 40.5% (CI, 24% to 56%), 32.3% (CI, 17% to 47%), and 34.6% (CI, 14% to 56%), respectively. At the time of evaluation, 22 of 39 patients had died, 7 of noninfectious complications and 14 of infections.
CONCLUSIONS:
Prednisone with or without COPBLAM/IMVP-16 treatment in AILD-type lymphoma leads to complete remissions in about half of the patients and in long-term, disease-free survival for one third.
AuthorsW Siegert, A Agthe, H Griesser, R Schwerdtfeger, G Brittinger, M Engelhard, R Kuse, M Tiemann, K Lennert, D Huhn
JournalAnnals of internal medicine (Ann Intern Med) Vol. 117 Issue 5 Pg. 364-70 (Sep 1 1992) ISSN: 0003-4819 [Print] UNITED STATES
PMID1380221 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)
Chemical References
  • Bleomycin
  • Procarbazine
  • Vincristine
  • Etoposide
  • Doxorubicin
  • Cyclophosphamide
  • Ifosfamide
  • Prednisone
  • Methotrexate
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Bleomycin (administration & dosage)
  • Cyclophosphamide (administration & dosage)
  • Doxorubicin (administration & dosage)
  • Etoposide (administration & dosage)
  • Female
  • Humans
  • Ifosfamide (administration & dosage)
  • Immunoblastic Lymphadenopathy (drug therapy)
  • Lymphoma, T-Cell (drug therapy)
  • Male
  • Methotrexate (administration & dosage)
  • Middle Aged
  • Prednisone (administration & dosage, therapeutic use)
  • Procarbazine (administration & dosage)
  • Prospective Studies
  • Survival Analysis
  • Vincristine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $490.00 USD